Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib
[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton’s tyrosine kinase ibrutinib.